Mineralys Therapeutics, Inc.
MLYS
$14.25
$0.755.56%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 78.79% | 62.19% | 53.08% | 74.22% | 83.84% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 86.81% | 128.77% | 187.05% | 136.73% | 176.89% |
Operating Income | -86.81% | -128.77% | -187.05% | -136.73% | -176.89% |
Income Before Tax | -100.69% | -147.55% | -237.81% | -149.90% | -168.81% |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -100.69% | -147.55% | -237.81% | -149.90% | -168.81% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -100.69% | -147.55% | -237.81% | -149.90% | -168.81% |
EBIT | -86.81% | -128.77% | -187.05% | -136.73% | -176.89% |
EBITDA | -- | -- | -- | -- | -- |
EPS Basic | -61.02% | -98.42% | -172.10% | -37.83% | 65.07% |
Normalized Basic EPS | -61.02% | -98.46% | -172.08% | -37.84% | 65.06% |
EPS Diluted | -61.02% | -98.42% | -172.10% | -37.83% | 65.07% |
Normalized Diluted EPS | -61.02% | -98.46% | -172.08% | -37.84% | 65.06% |
Average Basic Shares Outstanding | 24.63% | 24.75% | 24.15% | 81.31% | 669.47% |
Average Diluted Shares Outstanding | 24.63% | 24.75% | 24.15% | 81.31% | 669.47% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |